Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor
Aviceda Therapeutics aims to secure $200 million in financing for their latest project. The Boston-based biotech company is on a...
Aviceda Therapeutics aims to secure $200 million in financing for their latest project. The Boston-based biotech company is on a...
When Donald Trump surprisingly won the election on November 8th, the stock market took a hit at first. However, since...
The Google November 2024 Core Update has been making waves in the world of search rankings lately. Although it officially...
Today, let's talk about the latest news in finance and securities. If you're wondering what's been happening in the world...
ong-standing legal battle between Live Nation and Thomas “Tommy Dorfman” Dorfman has caught the attention of New Jersey Mayor Michele...
The microcarrier market is expected to see significant growth over the next decade, according to recent research. Market analysis shows...
Freddie Mac is well known in the world of finance and housing, but what exactly does this company do? Let's...
In a recent ruling, U.S. District Judge Ann Aiken has determined that the state of Oregon is responsible for covering...
On November 25th, there was a notable insider sell at Brinker International by SVP Daniel Fuller, as reported in a...
On November 25, Jean-Pierre Millon, Director at CVS Health, made a significant insider purchase of 2,200 shares of CVS Health...
Catalyst Bancorp Inc. recently made an important update that we want to share with you. The main points are in...
As global markets continue to reach new heights, recent positive reports on U.S. jobless claims and home sales are adding...